ID: ALA2165607

Max Phase: Preclinical

Molecular Formula: C12H14N2O2

Molecular Weight: 218.26

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCc1cccc(OCc2cc(=O)[nH][nH]2)c1

Standard InChI:  InChI=1S/C12H14N2O2/c1-2-9-4-3-5-11(6-9)16-8-10-7-12(15)14-13-10/h3-7H,2,8H2,1H3,(H2,13,14,15)

Standard InChI Key:  TWIIJBHVCFCLDC-UHFFFAOYSA-N

Associated Targets(Human)

Superoxide dismutase 173 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 218.26Molecular Weight (Monoisotopic): 218.1055AlogP: 1.84#Rotatable Bonds: 4
Polar Surface Area: 57.88Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.56CX Basic pKa: CX LogP: 1.64CX LogD: 1.43
Aromatic Rings: 2Heavy Atoms: 16QED Weighted: 0.82Np Likeness Score: -0.90

References

1. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB..  (2012)  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.,  55  (1): [PMID:22191331] [10.1021/jm2014277]

Source